Has Jessica Stein, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,776 in general payments to Jessica Stein, MD across 42 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jessica Stein, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jessica Stein, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jessica Stein, MD

Rheumatology · Norwalk, CTNPI 1689697377

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,357 of the $1,776 with a category attached, or 76.4%. 9 manufacturers reported payments, led by Johnson & Johnson at 48.2% of the total.

$1,776in general payments, 2019–2025

Across 42 payments — averaging $42.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Johnson & Johnson$856
Amgen$390
AbbVie$178
AstraZeneca$148
UCB, Inc.$65
GSK$62
plus $78 from 3 others

What the payments were for

Food & beverage$1,35776%
Education$41824%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Johnson & Johnson	8	$856
Amgen	11	$390
AbbVie	12	$178
AstraZeneca	2	$148
UCB, Inc.	2	$65
GSK	4	$62
E.r. Squibb & Sons, L.L.C.	1	$29
Genentech USA, Inc.	1	$26
Abbott	1	$23

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,776 in reported general payments places this provider in the 60th percentile of 118 rheumatology providers in Connecticut.

See all rheumatology providers in Connecticut →

Medicare billing

Part B allowed, 2024

$120,231

Medicare patients

175

Services billed

4,845

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Humira(Cf) PenAdalimumab	33	$215,953
Cyltezo(Cf) PenAdalimumab-Adbm	13	$85,932
ForteoTeriparatide	14	$59,928
ProliaDenosumab	24	$41,425
OtrexupMethotrexate/Pf	11	$10,654
Hydroxychloroquine Sulfate	242	$7,831
MethotrexateMethotrexate Sodium	146	$3,541
Colchicine	20	$2,558
Duloxetine Hcl	107	$2,102
Risedronate Sodium	18	$1,955
Leflunomide	55	$1,648
Prednisone	226	$1,552
Gabapentin	126	$1,444
Azathioprine	18	$1,120
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen	23	$932

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
AmgenProlia	$390	$41,42524 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 118 rheumatology providers in Connecticut.

Other rheumatology in Norwalk

Stuart NovackNorwalk$3K
Patrick WebsterNorwalk$2K
Kenneth MillerDanbury$873K
Robert SchoenGuilford$638K
Bret SohnStamford$447K
Fotios KoumpourasNorth Haven$314K
James SeiboldFarmington$300K
Michael SpiegelDanbury$215K
John MagaldiTorrington$157K
Archana SharmaBristol$98K

See the full list for Connecticut →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →